文献速递膀胱癌与上尿路尿路上皮癌

高级别T1期膀胱癌与肌层浸润性膀胱癌中PD-L1的差异表达及其预后意义

Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
PubMed 文献 · J Urol · 2017-05-06

研究纳入140例经尿道电切诊断为高级别T1期膀胱癌并接受卡介苗治疗的患者,中位随访7.4年,用免疫组化检测初诊电切标本PD-L1。肿瘤细胞PD-L1阳性6例(4%),肿瘤免疫细胞浸润PD-L1阳性48例(34.3%);在106例随访充分患者中PD-L1阳性与疾病结局、原位癌均无显著相关,肿瘤细胞PD-L1阳性在高级别T1期显著低于肌层浸润性膀胱癌(p<0.001)。

要点

  • 高级别T1期膀胱癌中肿瘤细胞PD-L1阳性率低(6/140,4%),免疫细胞浸润PD-L1阳性率较高(48/140,34.3%)。
  • 106例随访充分患者中,肿瘤细胞PD-L1阳性与疾病结局无显著相关(p=0.3),免疫细胞浸润PD-L1阳性亦无显著相关(p=0.47)。
  • 肿瘤细胞PD-L1阳性在高级别T1期膀胱癌中显著低于肌层浸润性膀胱癌(p<0.001)。

核心结论

  • PD-L1在高级别T1期膀胱癌的肿瘤免疫细胞浸润中广泛表达,但在肿瘤细胞中不广泛表达。
  • 未发现PD-L1阳性与疾病结局或原位癌存在相关性。
  • 肿瘤细胞PD-L1阳性在高级别T1期膀胱癌中显著低于肌层浸润性膀胱癌(p<0.001)。

研究设计与样本

  • 回顾性分析140例经尿道电切初诊为高级别T1期膀胱癌、随后接受卡介苗治疗的患者甲醛固定石蜡包埋肿瘤标本,中位随访7.4年。
  • 采用小鼠单克隆抗PD-L1抗体(405.9A11)免疫组化评估初诊电切标本PD-L1阳性。
  • 肿瘤细胞PD-L1阳性定义为5%肿瘤细胞膜着色;肿瘤免疫细胞浸润PD-L1阳性根据浸润范围和阳性细胞百分比评分。
  • 采用Fisher精确检验评估PD-L1阳性与疾病结局、原位癌及高级别T1期与肌层浸润性膀胱癌差异的关联。

主要发现

  • 140例高级别T1期膀胱癌中,肿瘤细胞PD-L1阳性6例(4%),肿瘤免疫细胞浸润PD-L1阳性48例(34.3%)。
  • 106例随访充分患者中,肿瘤细胞PD-L1阳性与疾病结局无显著相关(p=0.3),肿瘤免疫细胞浸润PD-L1阳性与疾病结局无显著相关(p=0.47)。
  • PD-L1阳性与原位癌存在无显著相关。
  • 肿瘤细胞PD-L1阳性在高级别T1期膀胱癌中显著低于肌层浸润性膀胱癌(p<0.001)。

关键数值与推荐

  • 肿瘤细胞PD-L1阳性判定阈值:5%肿瘤细胞膜着色。
  • 肿瘤细胞PD-L1阳性率:高级别T1期膀胱癌6/140(4%)。
  • 肿瘤免疫细胞浸润PD-L1阳性率:高级别T1期膀胱癌48/140(34.3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PD-L1 is expressed on tumor cells and tumor immune cell infiltrates. In metastatic bladder cancer increased tumor immune cell infiltrate PD-L1 positivity correlated with better overall survival. However, to our knowledge in high grade T1 bladder tumors positivity on tumor cells and tumor immune cell infiltrates, and correlation with outcomes or pathological features remain unknown. MATERIALS AND METHODS: Formalin fixed, paraffin embedded tumor samples from 140 patients with clinically annotated, high grade T1 bladder tumors were retrieved. All patients were initially diagnosed with high grade T1 bladder tumors by transurethral resection, subsequently received bacillus Calmette-Guérin and had a median followup of 7.4 years. PD-L1 positivity on initial transurethral resection was evaluated by immunohistochemistry using a mouse monoclonal antiPD-L1 antibody (405.9A11). Tumor cell PD-L1 positivity was defined as staining of 5% of the tumor cell membrane. Tumor immune cell infiltrate PD-L1 positivity was scored based on the extent of infiltrate and the percent of positive cells. The Fisher exact test was used to assess associations of PD-L1 positivity with disease outcomes, carcinoma in situ presence and the difference between high grade T1 bladder tumors and muscle invasive bladder cancer. RESULTS: Among 140 patients with high grade T1 bladder tumors tumor cells and tumor immune cell infiltrate PD-L1 positivity was seen in 6 (4%) and 48 (34.3%), respectively. In a subset of 106 patients with adequate followup PD-L1 positivity did not correlate with disease outcomes on tumor cells (p = 0.3) or on tumor immune cell infiltrates (p = 0.47). PD-L1 positivity also did not correlate with the presence of carcinoma in situ. Tumor cell PD-L1 positivity was significantly less in high grade T1 bladder tumors than in muscle invasive bladder cancer (p <0.001). CONCLUSIONS: PD-L1 is widely expressed on tumor immune cell infiltrates but not on tumor cells in high grade T1 bladder tumors. We did not find a correlation between PD-L1 positivity and outcomes or carcinoma in situ presence. Tumor cell PD-L1 positivity is significantly lower in high grade T1 bladder tumors than in muscle invasive bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Wankowicz SAM, Werner L, Orsola A, et al. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017. PMID: 28487100. doi:10.1016/j.juro.2017.04.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。